Stock Insights on Boston Scientific Corporation (NYSE:BSX)

[PRnewswire] Boston Scientific Corporation (NYSE:BSX) was review for its WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device, the U.S. Food and Drug Administration (FDA) Circulatory System Devices Panel of the Medical Devices Advisory Committee voted in favor of the Device. By a vote of 6 to 5 (with 1 abstention) the Panel concluded that the benefits of the WATCHMAN Device outweigh the potential risks. Furthermore, the Panel voted that there is reasonable assurance that the Device is safe (12 yes to 0 no). On the question of reasonable assurance of effectiveness, the Panel vote was unfavorable (6 yes to 7 no). The Panel provided substantial input and guidance related to the proposed Indications for Use and target patient population. There was widespread agreement among the Panel members that the Device provides a much needed alternative to long-term anticoagulation for some patients.Stock PerformanceTaking a look at the company’s recent performance, Boston Scientific Corporation (BSX) reported Second quarter earnings for fiscal 2014 on July 24^th. The company reported actual earnings per share of $0.18 against the consensus Street estimate of $0.19. Boston Scientific Corp posted revenue of $1.87 billion exactly as it was estimated.Boston Scientific Corp is currently valued at $15.11 billion and closed the last trading session at $11.56. The stock has a 50-day moving average of $12.32 and a 200-day moving average of $12.80.

Is this a Buying Opportunity?There are currently eighteen analysts that we track that cover the stock. Of those eighteen, ten have a Buy rating and eight have a hold rating. On a consensus basis this yields a score of 2.56 and a Buy. The combined price objective of these covering analysts is $13.99, which represents a 17.25% upside difference to the last closing price.The most recent analyst activity consisted of Needham & Company LLC who Initiated Coverage with Hold stance on the company. On the date of the report, the stock closed at $11.81.Another research firm weighing in recently was Zacks who reiterated their neutral rating on the stock. On August 13^th Zacks updated their price target on the stock at $13.00, a 4.17% upside to the current price. On the day of the report, BSX shares closed at $12.48.Company ProfileBoston Scientific Corporation (BSX) develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in three segments: Cardiovascular, Rhythm Management, and MedSurg. It offers interventional cardiology products, including coronary stent systems used in the treatment of coronary artery disease; coronary technology products used to treat patients with atherosclerosis; intraluminal catheter-directed ultrasound imaging catheters and systems for use in coronary arteries and heart chambers, as well as peripheral vessels; and structural heart therapy systems. The company also provides stents etc.